Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 26, 2026.

Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection

David S. Fedson, Steven M. Opal, Ole Martin Rordam

mBio · 2020 · CC BY

doi:10.1128/mbio.00398-20

Abstract

Patients with COVID-19 infection are at risk of acute respiratory disease syndrome (ARDS) and death. The tissue receptor for COVID-19 is ACE2, and higher levels of ACE2 can protect against ARDS. Angiotensin receptor blockers and statins upregulate ACE2. Clinical trials are needed to determine whether this drug combination might be used to treat patients with severe COVID-19 infection.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 26, 2026. Paragraph numbers are ours, so an answer can point at one.

COMMENTARY

The severe respiratory disease that has recently emerged in China is caused by a novel coronavirus (COVID-19). The virus is similar to the SARS coronavirus that spread internationally in 2003, infected more than 8,000 people, and killed almost 800. Infection with COVID-19 has now spread throughout the world, causing widespread social and economic disruption. To control its spread, Chinese officials have imposed extensive travel bans and quarantined large areas. Accelerated development of new vaccines and treatments is already under way. It is too early to know whether any of these efforts will contain the outbreak.

Thus far, patients hospitalized with severe COVID-19 infection have had pneumonia. Of 44,672 laboratory-confirmed patients, almost 5% have had critical illness and almost 50% of critically ill patients have died. The overall case fatality rate (2.3%) has been higher than that seen with seasonal influenza. Most deaths have involved older adults, many of whom have had underlying chronic illnesses. Although there is no known treatment for any coronavirus infection, investigators in China have undertaken several clinical trials. Except for corticosteroids, all of the drugs being tested target coronavirus replication. Unfortunately, very few of these antiviral drugs will be available to people who have been (or will be) infected with COVID-19. Yet, for those who develop severe disease, only one question matters: “will I live or die?” This is the question that clinical investigators should address. Could they discover a treatment that might reduce the severity of COVID-19 infection and improve patient survival?

In 2014, one of us suggested that statins might be used to treat patients with Ebola virus disease. A supply of a generic statin and a generic angiotensin receptor blocker (ARB) was sent to Sierra Leone. Experimental studies had shown that both drugs improved outcomes in experimental acute lung injury/acute respiratory disease syndrome (ARDS). In Sierra Leone, local physicians treated approximately 100 Ebola patients with a combination of the two drugs. They noted “remarkable improvement” in survival. Although there was no support for a proper clinical trial, the findings from this unconventional and poorly documented treatment experience were published. During the current Ebola outbreak in the Democratic Republic of the Congo (DRC), expensive vaccines are being used. Investigational monoclonal antibody preparations, but not inexpensive generic drug treatments, have been tested. There are preliminary signs that the DRC outbreak is coming under control, although the case fatality rate is still 66%.

An approach to treating patients with severe COVID-19 infection might be hiding in plain sight. The tissue receptor for the virus is ACE2, which is also the receptor for the SARS coronavirus. Several years ago, investigators in the Netherlands and elsewhere showed that ARBs and statins upregulate the activity of ACE2, and higher levels of ACE2 are associated with a reduced severity of ARDS. Both statins and ARBs target the host response to infection, not the virus. They act largely (although not exclusively) on endothelial dysfunction, which is a common feature of many virus infections. Both drugs counter endothelial dysfunction by affecting the ACE2/angiotensin-(1–7)/Mas and angiopoietin/Tie-2 signaling axes. Combination treatment with these two drugs appears to accelerate a return to homeostasis, allowing patients to recover on their own.

The host response is a major determinant of the pathogenesis of infectious diseases. We believe that investigators in China and elsewhere should undertake studies of patients with severe COVID-19 infection to determine whether targeting the host response with widely available and inexpensive generic drugs, like ARBs and statins, will improve their chances of survival. The studies would not have to be large; a successful clinical trial might require only 100 patients. Convincing evidence of the effectiveness of this treatment would suggest a syndromic approach to treating patients with other emerging infectious diseases, like Ebola and pandemic influenza, as well as everyday illnesses, like sepsis and pneumonia. The long-term benefits of these findings for global public health could be immense.

References 19

  1. 1.

    Chen Y, Liu Q, Guo D 2020 Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol 92:418–423. doi:.

    Not in our library10.1002/jmv.25681

  2. 2.

    Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z 7 2 2020 Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA doi:.

    Not in our library10.1001/jama.2020.1585

  3. 3.

    The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. 2020 The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020. China CDC Weekly 2:113–122. http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51. Accessed 18 February 2020.

    Not in our library

  4. 4.

    Fedson DS 2015 A practical treatment for patients with Ebola virus disease. J Infect Dis 21:661–662. doi:.

    Not in our library10.1093/infdis/jiu474

  5. 5.

    Shyamsundar M, McKeown STW, O'Kane CM, Craig TR, Brown V, Thickett DR, Matthay MA, Taggart CC, Backman JT, Elborn JS, McAuley DF 2009 Simvastatin decreases lipopoly-saccharide-induced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med 179:1107–1114. doi:.

    Not in our library10.1164/rccm.200810-1584oc

  6. 6.

    Chen W, Sharma R, Rizzo AN, Siegler JH, Garcia JG, Jacobson JR 2014 Role of claudin-5 in the attenuation of murine acute lung injury by simvastatin. Am J Respir Cell Mol Biol 50:328–336. doi:.

    Not in our library10.1165/rcmb.2013-0058oc

  7. 7.

    Shen L, Mo H, Cai L, Kong T, Zheng W, Ye J, Qi J, Xiao Z 2009 Losartan prevents sepsis-induced acute lung injury and decreases activation of nuclear factor kappaB and mitogen-activated protein kinases. Shock 3:500–506. doi:.

    Not in our library10.1097/shk.0b013e318189017a

  8. 8.

    Li Y, Cao Y, Zeng Z, Liang M, Xue Y, Xi C, Zhou M, Jiang W 2015 Angiotensin-converting enzyme 2/angiotensin-(1–7)/Mas axis prevents lipopolysaccharide-induced apoptosis of pulmonary microvascular endothelial cells by inhibiting JNK/NF-κB pathways. Sci Rep 5:8209. doi:.

    Not in our library10.1038/srep08209

  9. 9.

    Fedson DS 2016 Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola. Ann Transl Med 4:421. doi:.

    Not in our library10.21037/atm.2016.11.03

  10. 10.

    Fedson DS, Jacobson JR, Rordam OM, Opal SM 2015 Treating the host response to Ebola virus disease with generic statins and angiotensin receptor blockers. mBio 6:e00716-15. doi:.

    Not in our library10.1128/mbio.00716-15

  11. 11.
    Treating Ebola patients: a ‘bottom up’ approach using generic statins and angiotensin receptor blockers · 2015
    Not checked
  12. 12.

    Mulangu S, Dodd LE, Davey RT Jr, Tshiani Mbaya O, Proschan M, Mukadi D, Lusakibanza Manzo M, Nzolo D, Tshomba Oloma A, Ibanda A, Ali R, Coulibaly S, Levine AC, Grais R, Diaz J, Lane HC, Muyembe-Tamfum JJ, PALM Writing Group, Sivahera B, Camara M, Kojan R, Walker R, Dighero-Kemp B, Cao H, Mukumbayi P, Mbala-Kingebeni P, Ahuka S, Albert S, Bonnett T, Crozier I, Duvenhage M, Proffitt C, Teitelbaum M, Moench T, Aboulhab J, Barrett K, Cahill K, Cone K, Eckes R, Hensley L, Herpin B, Higgs E, Ledgerwood J, Pierson J, Smolskis M, Sow Y, Tierney J, Sivapalasingam S, Holman W, Gettinger N, Vallée D, Nordwall J, PALM Consortium Study Team. 2019 A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 381:2293–2303. doi:.

    Not in our library10.1056/nejmoa1910993

  13. 13.

    Fedson DS 2019 Treating Ebola in eastern DRC. Lancet Infect Dis 19:1059–1060. doi:.

    Not in our library10.1016/s1473-3099(19)30484-0

  14. 14.

    Wösten-van Asperen RM, Lutter R, Specht PA, Moll GN, van Woensel JB, van der Loos CM, van Goor H, Kamilic J, Florquin S, Bos AP 2011 Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1–7) or an angiotensin II receptor antagonist. J Pathol 225:618–627. doi:.

    Not in our library10.1002/path.2987

  15. 15.

    Tikoo K, Patel G, Kumar S, Karpe PA, Sanghavi M, Malek V, Srinivasan K 2015 Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: role of epigenetic histone modifications. Biochem Pharmacol 93:343–351. doi:.

    Not in our library10.1016/j.bcp.2014.11.013

  16. 16.

    Wösten-van Asperen RM, Bos AP, Bem RA, Dierdorp BS, Dekker T, van Goor H, Kamilic J, van der Loos CM, van den Berg E, Bruijn M, van Woensel JB, Lutter R 2013 Imbalance between pulmonary angiotensin-converting enzyme and angiotensin-converting enzyme 2 activity in acute respiratory distress syndrome. Pediatr Crit Care Med 14:e438–e441. doi:.

    Not in our library10.1097/pcc.0b013e3182a55735

  17. 17.

    Steinberg BE, Goldenberg NM, Lee WL 2012 Do viral infections mimic bacterial sepsis? The role of microvascular permeability: a review of mechanisms and methods. Antiviral Res 93:2–15. doi:.

    Not in our library10.1016/j.antiviral.2011.10.019

  18. 18.

    Pirofski LA, Casadevall A 2018 The Damage-Response Framework as a tool for the physician-scientist to understand the pathogenesis of infectious diseases. J Infect Dis 218(Suppl 1):S7–S11. doi:.

    Not in our library10.1093/infdis/jiy083

  19. 19.

    Fedson DS 2018 Clinician-initiated research on treating the host response to pandemic influenza. Hum Vaccin Immunother 14:790–795. doi:.

    Not in our library10.1080/21645515.2017.1378292

Cited by papers we hold 9

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.